Forty Seven Overview

  • Founded
  • 2014
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 68
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $4.7B
Latest Deal Amount

Forty Seven General Information

Description

Forty Seven Inc is a clinical-stage immuno-oncology company. It is engaged in developing novel checkpoint therapies to activate macrophages and help the patients in their fight against cancer. It founded that blocking CD47, a key signaling molecule that is overexpressed on cancer cells renders tumors susceptible to macrophages. It is also preparing investigational compounds into clinical testing. FSI-174, an anti-cKIT antibody, is being developed in combination with magrolimab as a novel, all-antibody conditioning regimen to address the limitations of current stem cell transplantation conditioning regimens. FSI-189, an anti-SIRP-alpha antibody, is being developed for the treatment of cancer, and certain non-oncology conditions, including transplantation conditioning.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Acquirer
Primary Office
  • 1490 O'Brien Drive
  • Suite A
  • Menlo Park, CA 94025
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Forty Seven Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 07-Apr-2020 $4.7B 00000 00.00 Completed Generating Revenue/Not Profitable
7. Secondary Transaction - Open Market 00000 Completed Clinical Trials - Phase 1
6. Secondary Transaction - Open Market 00000 Completed Clinical Trials - Phase 1
5. PIPE 07-Aug-2019 000 00000 Completed Clinical Trials - Phase 1
4. IPO 28-Jun-2018 00000 00000 00000 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series B) 17-Oct-2017 0000 00000 00000 Completed Clinical Trials - Phase 1
2. Grant 05-Apr-2017 $14.2M $74.8M Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A) 01-Mar-2016 $74.8M $74.8M 00000 Completed Startup
To view Forty Seven’s complete valuation and funding history, request access »

Forty Seven Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 000
Series A2 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A1 34,400,000 $0.000100 8% $1 $1 1x $1 17.55%
To view Forty Seven’s complete cap table history, request access »

Forty Seven Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Forty Seven Inc is a clinical-stage immuno-oncology company. It is engaged in developing novel checkpoint therapies to a
Biotechnology
Menlo Park, CA
68 As of 2019
00000
0.00 0000-00-00
000000&0 00000

0000000

, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut
0000000000000
Cambridge, MA
000 As of 0000
00000
000000 - 000 00000

0000 000

inim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis
0000000000000
Santa Monica, CA
000 As of 0000
00000
000 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Forty Seven Competitors (33)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Avrobio Formerly VC-backed Cambridge, MA 000 00000 000000 - 000 00000
0000 000000 Formerly VC-backed Santa Monica, CA 000 00000 000000&0 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
00000000 Formerly VC-backed Planegg, Germany 000 00000 000000000 00000
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
You’re viewing 5 of 33 competitors. Get the full list »

Forty Seven Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Forty Seven Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Blackstone Life Sciences PE/Buyout Minority 000 0000 000000 0
California Institute for Regenerative Medicine Government Minority 000 0000 000000 0
GV Corporate Venture Capital Minority 000 0000 000000 0
Lightspeed Venture Partners Venture Capital Minority 000 0000 000000 0
Sutter Hill Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

Forty Seven Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 0000000000 ( 01-Jun-2018 000000000 00000 00 Buildings and Property
To view Forty Seven’s complete investments history, request access »